NanoViricides President Presents at the 2nd Annual Conference of the American Society for NanoMedicine

(Nanowerk News) NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM). This was a joint meeting, co-sponsored by the Office of AIDS Research, National Institutes of Health (NIH), the Division of AIDS, National Institute of Allergy and Infectious Diseases of the NIH, and ASNM. The conference was held at the Bolger Center, Washington, DC, October 14-16, 2010. Anil R Diwan, PhD, President of the Company, spoke in the panel on "Policy, Patents, and Commercialization". The panel covered the business challenges that nanomedicine companies face in bringing leading edge medical products into commercialization.
"Nanomedicines represent the next therapeutic plateau in the treatment of many diseases," said Dr. Diwan, adding, "The level of effectiveness achieved with these novel, targeted, specific, therapies is far greater than what has been attained thus far."
Dr. Diwan reviewed the accomplishments of NanoViricides, Inc. He discussed the platform technology upon which the nanoviricides® drug candidates are based. Nanoviricides are designed to complete the job of rendering the virus particle non-infectious without assistance from the immune system, he said. A nanoviricide accomplishes this by mimicking the features of the cell surface to which a virus binds. He presented the very promising results obtained by the Company in testing its nanoviricides drug candidates against a number of diseases including Influenza, viral diseases of the Eye, Herpes Simplex Virus (HSV), Dengue Virus, and HIV. He then went on to discuss the challenges faced by nanomedicine companies in commercializing novel, cutting edge therapies. The presentation was attended by leading scientists in the field of nanomedicine as well as scientists from the sponsoring NIH agencies. The presentation was well received.
About the American Society for NanoMedicine (ASNM)
The American Society for NanoMedicine (ASNM) is a professional, academic and medical society dedicated to advancing research in nanomedicine. It comprises of members drawn from throughout the fields of nanotechnology, engineering, and the biomedical sciences with the common goal of advancing nanomedicine research for the realization of the potential it has to benefit the global community. ASNM is an open, democratic, and professional nonprofit organization.
About NanoViricides
NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Source: NanoViricides (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: